Literature DB >> 19823171

Isolation of targeting nanobodies against co-opted tumor vasculature.

Ilse Roodink1, Maarten Franssen, Malou Zuidscherwoude, Kiek Verrijp, Tom van der Donk, Jos Raats, William Pj Leenders.   

Abstract

Tumor vasculature is in general highly heterogeneous. This characteristic is most prominent in high-grade gliomas, which present with areas of angiogenic growth, next to large areas of diffuse infiltrative growth in which tumor cells thrive on pre-existent brain vasculature. This limits the effectiveness of anti-angiogenic compounds as these will not affect more matured and co-opted vessels. Therefore, additional destruction of existing tumor vasculature may be a promising alternative avenue to effectively deprive tumors from blood. This approach requires the identification of novel tumor vascular targeting agents, which have broad tumor vessel specificities, ie are not restricted to newly formed vessels. Here, we describe the generation of a phage library displaying nanobodies that were cloned from lymphocytes of a Llama which had been immunized with clinical glioma tissue. In vivo biopanning with this library in the orthotopic glioma xenograft models E98 and E434 resulted in the selection of various nanobodies which specifically recognized glioma vessels in corresponding glioma xenografts. Importantly, also nanobodies were isolated which discriminated incorporated pre-existent vessels in highly infiltrative cerebral E434 xenografts from normal brain vessels. Our results suggest that the generation of nanobody-displaying immune phage libraries and subsequent in vivo biopanning in appropriate animal models is a promising approach for the identification of novel vascular targeting agents.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19823171     DOI: 10.1038/labinvest.2009.107

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  6 in total

1.  An innovative strategy to identify new targets for delivering antibodies to the brain has led to the exploration of the integrin family.

Authors:  Céline Cegarra; Béatrice Cameron; Catarina Chaves; Tarik Dabdoubi; Tuan-Minh Do; Bruno Genêt; Valérie Roudières; Yi Shi; Patricia Tchepikoff; Dominique Lesuisse
Journal:  PLoS One       Date:  2022-09-15       Impact factor: 3.752

2.  Intravenous infusion of phage-displayed antibody library in human cancer patients: enrichment and cancer-specificity of tumor-homing phage-antibodies.

Authors:  Girja S Shukla; David N Krag; Elena N Peletskaya; Stephanie C Pero; Yu-Jing Sun; Chelsea L Carman; Laurence E McCahill; Thomas A Roland
Journal:  Cancer Immunol Immunother       Date:  2013-06-05       Impact factor: 6.968

Review 3.  Combinatorial approaches for the identification of brain drug delivery targets.

Authors:  Charles C Stutz; Xiaobin Zhang; Eric V Shusta
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

4.  In vivo phage display screening for tumor vascular targets in glioblastoma identifies a llama nanobody against dynactin-1-p150Glued.

Authors:  Sanne A M van Lith; Ilse Roodink; Joost J C Verhoeff; Petri I Mäkinen; Jari P Lappalainen; Seppo Ylä-Herttuala; Jos Raats; Erwin van Wijk; Ronald Roepman; Stef J Letteboer; Kiek Verrijp; William P J Leenders
Journal:  Oncotarget       Date:  2016-11-01

Review 5.  Critical considerations for targeting colorectal liver metastases with nanotechnology.

Authors:  Usman Arshad; Paul A Sutton; Marianne B Ashford; Kevin E Treacher; Neill J Liptrott; Steve P Rannard; Christopher E Goldring; Andrew Owen
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-09-30

Review 6.  Filamentous Bacteriophage-A Powerful Carrier for Glioma Therapy.

Authors:  Yicun Wang; Jiyao Sheng; Jin Chai; Cuilin Zhu; Xin Li; Wei Yang; Ranji Cui; Tongtong Ge
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.